PathoGene Reels in $750K in Seed Funds to Develop PCR-Based Infectious Disease Dxs

PathoGene Reels in $750K in Seed Funds to Develop PCR-Based Infectious Disease Dxs

   The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.